Passionate about Developing
the Next Generation of Therapeutics

Solid Record
of Building
Great Companies

Deep
Industry
Experience

Strong R&D
and Regulatory
Capabilities

Extensive Network
within Industry
and Academia

Michael Jaharis

Co-Founder
1928 – 2016

Michael Jaharis co-founded Vatera Healthcare Partners and was an advisor to the firm until his passing in 2016. He was a legend in the industry and will be remembered for his passion for innovation, creativity and great generosity.

Kevin Ferro

Chief Executive Officer,
Chief Investment Officer & Co-Founder

Kevin Ferro, a co-founder of Vatera Healthcare Partners, has over two decades of investment experience, with a focus on biopharmaceuticals for almost 15 years.

Cecilia Gonzalo

Managing Director

Cecilia Gonzalo is responsible for overseeing Vatera Healthcare Partners’ portfolio companies and sourcing new investments in the biopharmaceutical industry.

Sundar Kodiyalam

Managing Director & Co-Founder

Sundar Kodiyalam, a co-founder of Vatera Healthcare Partners, helps manage our investments and shares his insights and guidance with our portfolio companies and team.

Thomas Koestler, PhD

Executive Director

Dr. Thomas Koestler brings his deep network and extensive knowledge of the pharmaceutical industry to the Vatera Healthcare Partners management team and its portfolio companies.

Justin Sun

Director

Justin Sun focuses on sourcing new investments while also working closely with Vatera Healthcare Partners’ existing portfolio companies.

Michael Beecham

Senior Associate

Michael Beecham is responsible for analyzing new investment opportunities and offering support for Vatera Healthcare Partners’ portfolio companies.

Michael Allen

Chief Financial Officer

Michael Allen brings over 20 years of financial management experience and oversees Vatera Healthcare Partners’ financial operations.

Christopher Burden

Chief Operating Officer

Chris Burden draws on his more than 20 years of private equity legal and business experience to assist Vatera Healthcare Partners with a wide range of transactional and business management matters.

Anna Kim

General Counsel

Anna Kim is responsible for Vatera Healthcare Partners’ legal, structuring and compliance-related activities.

Michael Jaharis

Co-Founder
1928 – 2016

Michael Jaharis, a co-founder of Vatera Healthcare Partners, was a legend in the pharmaceutical industry. His passion for pharmaceutical innovation combined with a long-term vision of clinical and market needs enabled the successes with a number of pharmaceutical companies, including Key Pharmaceuticals, Kos Pharmaceuticals and Vatera Healthcare Partners’ investment in Pearl Therapeutics. With a keen understanding of their businesses, Michael continued to invest in these companies even as they faced the inevitable ups and downs of the pharmaceutical business.

Success in these pharmaceutical ventures has enabled the Jaharis family to give back through their philanthropic contributions to numerous educational, cultural and religious institutions and humanitarian causes. Generations will remember and benefit not just from Michael Jaharis’ contributions to the pharmaceutical industry, but also from his deep commitment and generosity to the causes in which he believed. Inspired by their passion for charitable causes, Michael Jaharis and his wife Mary created the Jaharis Family Foundation, Inc.

Among his many public service activities, Michael Jaharis was a board member of several prominent non-profit and educational institutions, including Trustee Emeritus of Tufts University in Boston, MA; Chairman of the Board of Overseers for the School of Medicine, Tufts University; Member of the Columbia University Medical Center Board of Visitors; Member of the Board of Overseers of the Weill Cornell Medical College and Graduate School of Medical Sciences; and Director of The Onassis Public Benefit Foundation (USA).

After serving in the U.S. Army during the Korean War, Michael Jaharis became a sales representative for Miles Laboratories while earning his law degree at night from DePaul University. Along with Phil Frost, he acquired control of Key Pharmaceuticals in 1970. Michael Jaharis developed and grew Key Pharmaceuticals from near bankruptcy into a thriving innovative pharmaceutical company that produced and marketed some of the best-selling asthma and cardiovascular products in the U.S. at the time. He turned the company around, revamped its product line and merged it with Schering-Plough in 1986 for $836 million. Michael Jaharis then launched Kos Pharmaceuticals, named for the Greek island where Hippocrates founded the science of medicine. Built on the foundation and legacy of Key Pharmaceuticals, Kos focused on the treatment of chronic diseases, developing products in the cardiovascular, metabolic and respiratory areas. Ultimately, Kos was acquired by Abbott Laboratories in 2006 for $4.2 billion.

Kevin Ferro

Chief Executive Officer, Chief Investment Officer
and Co-Founder

Current Boards

Alvogen (Observer)
Arisaph Pharmaceuticals, Inc. (Chairman)
ImmusanT, Inc. (Chairman)
Melinta Therapeutics, Inc.

Select Past Boards

Pearl Therapeutics, Inc. (Chairman)
Kos Pharmaceuticals, Inc.

Education

Harvard College, AB in Government

Kevin Ferro is the Chief Executive Officer of Vatera Holdings LLC. Vatera Healthcare Partners is the dedicated healthcare venture capital and private equity investing arm of Vatera Holdings. Kevin has over two decades of investment experience, and has focused on biopharmaceutical investments for almost 15 years. Kevin has demonstrated an ability to identify numerous compelling opportunities where Vatera builds and partners with management teams to create innovation and value. His focused approach and deep relationships enable him to help companies navigate challenges through all stages of development.

Prior to forming Vatera, Kevin founded Ferro Capital LLC, an alternative investment firm managing portfolios for clients in the U.S. and Europe. Before that, Kevin was the Global Head of Alternative Investment Strategies for Commerzbank, Germany’s second-largest listed bank, where he managed alternative investment programs for the bank and its clients. Prior to Commerzbank, he was a Vice President at D. E. Shaw & Co., L.P. Kevin is a member of the Board of Directors of the Jaharis Family Foundation, Inc. Kevin holds an AB in Government from Harvard College.

Cecilia Gonzalo

Managing Director

Current Boards

Melinta Therapeutics, Inc.

Select Past Boards

Allos Therapeutics, Inc.
Bausch & Lomb Incorporated (Observer)
Edgemont Pharmaceuticals, LLC
Eurand N.V.
Ganic Pharmaceuticals, Inc.
Grupo Biotoscana
LaVie Care Centers
Prestwick Pharmaceuticals, Inc.
Talon Therapeutics, Inc.

Education

Harvard Business School, MBA
Harvard College, AB in Biochemical Sciences

Cecilia Gonzalo is responsible for sourcing new investments and overseeing Vatera Healthcare Partners’ existing investments in biopharmaceuticals. She has 20 years of investment and finance experience, of which the last 15 are in the healthcare sector. Combining her background in biochemical sciences and finance, Cecilia has invested in a number of innovative healthcare companies with the goal of bringing value-added products and services to market while generating attractive investment returns. Over the years, Cecilia has effectively identified attractive investment opportunities and partnered with talented management teams to create long-standing value while serving patients’ unmet needs.

Cecilia joined the firm in 2015. Before that, she was a Managing Director at Essex Woodlands, a healthcare-focused growth equity firm, where she worked on investing across the healthcare sector in the U.S., Latin America and Europe. Prior to Essex Woodlands, Cecilia spent 12 years at Warburg Pincus LLC, a global private equity firm, where she was a Managing Director focusing on healthcare investments. Before Warburg Pincus LLC, she was an Analyst at Goldman, Sachs & Co. both in the Investment Banking Division and Principal Investment Area. Cecilia is currently a board member and Treasurer of the Harvard Business School Healthcare Alumni Association. Cecilia holds an AB in Biochemical Sciences from Harvard College and an MBA from Harvard Business School.

Sundar Kodiyalam

Managing Director and Co-Founder

Current Boards

Arisaph Pharmaceuticals, Inc. (Observer)
ImmusanT, Inc.
Melinta Therapeutics, Inc. (Observer)

Select Past Boards

Edgemont Pharmaceuticals, LLC
Pearl Therapeutics, Inc.

Education

Ohio State University, MS in Pharmaceutical Administration
Madras University, India, B Pharm in Pharmacy

Sundar Kodiyalam, a co-founder of Vatera Healthcare Partners, helps manage our investments while sharing his insights and guidance with our portfolio companies and team. Sundar has nearly 20 years of operating experience in the biotechnology and biopharmaceutical sectors with an emphasis on therapeutic products and almost 10 years of healthcare investing experience. His deep knowledge of the industry, ability to drive results and extensive network have enabled him to effectively partner with our management teams and serve as an invaluable resource as they grow their businesses.

Before joining the firm in 2007, Sundar was Senior Vice President of Commercial Development & New Business Ventures at Kos Pharmaceuticals, Inc. Sundar was a key member of the management team that worked on the sale of Kos Pharmaceuticals to Abbott Laboratories. Prior to Kos Pharmaceuticals, Sundar was Vice President of Commercial Development at Ortec International. Sundar’s experience at large pharmaceutical companies includes 3 years at Schering-Plough Corporation as Director of Business Development & Licensing and 10 years at Novartis Pharmaceuticals Corporation in domestic and international marketing roles. Sundar holds a B Pharm in Pharmacy from Madras University in India and an MS in Pharmaceutical Administration from Ohio State University.

Thomas Koestler, PhD

Executive Director

Current Boards

Arisaph Pharmaceuticals, Inc.
ImmusanT, Inc.
Melinta Therapeutics, Inc. (Chairman)
Momenta Pharmaceuticals, Inc.

Select Past Boards

Edgemont Pharmaceuticals, LLC (Chairman)
Novo Nordisk A/S
Pearl Therapeutics, Inc.
ReSearch Pharmaceuticals Services, Inc.

Education

State University of New York at Buffalo, Roswell Park Memorial Institute, PhD in Medicine/Pathology
Daemen College, BS in Biology

Dr. Tom Koestler brings his deep network and extensive knowledge of the pharmaceutical industry to the Vatera Healthcare Partners management team. In his nearly 30-year career in the industry, Tom established a track record of building high-performance teams that drove global success in research and development. Under his leadership at Schering-Plough Corporation, the company developed an industry-leading pipeline that contributed to the turnaround of the business. Tom is credited with over 80 product approvals, including more than 30 New Molecular Entities.

Prior to joining the Vatera team in 2010, Tom was Executive Vice President of Schering-Plough Corporation and President of Schering-Plough Research Institute, which he joined in 2003. Before that, Tom held the position of Senior Vice President, Global Head Regulatory Affairs at Pharmacia Corporation. Previously, he was Senior Vice President, Global Head, Drug Regulatory Affairs/Compliance Assurance (GCP-QA) Professionals at Novartis Pharmaceuticals Corporation. Tom also held senior positions at Ortho-McNeil Pharmaceutical Corporation, and Bristol-Myers Squibb Company and Westwood Pharmaceuticals, Inc. Tom is currently on the Scientific Advisory Board of Allergan plc and previously was Chair of the Bausch & Lomb Incorporated Scientific Advisory Board from 2011 to 2013. Tom holds a BS in Biology from Daemen College and a PhD in Medicine and Pathology from the State University of New York at Buffalo, Roswell Park Memorial Institute.

Justin Sun

Director

Current Boards

ImmusanT, Inc.

Select Past Boards

Edgemont Pharmaceuticals, LLC

Education

Yale University, BA in Economics

Justin Sun focuses on sourcing new investments while also working closely with Vatera Healthcare Partners’ existing portfolio companies. He has over 12 years of experience in the healthcare sector, with the last 9 years focused on healthcare venture capital and private equity investing.

Justin joined the firm in 2009. Before that, he was an Analyst at Aisling Capital, a leading private equity firm dedicated to life sciences investing. Prior to Aisling, he was an Analyst in the Healthcare Investment Banking Division of Thomas Weisel Partners, where he focused on mergers and acquisitions and equity financing transactions across the healthcare industry. Justin holds a BA in Economics from Yale University.

Michael Beecham

Senior Associate

Education

University of Pennsylvania, BSE in Bioengineering

Michael Beecham is responsible for analyzing new investment opportunities and offering support for Vatera Healthcare Partners’ portfolio companies. He has over five years of experience in the life sciences and healthcare sector.

Before joining the firm in 2016, Michael was an Associate with OrbiMed Advisors LLC. Prior to that, he was an Associate in the Healthcare Private Equity Group of American Capital, Ltd., and a Senior Consultant in the Life Sciences Group of Easton Associates LLC (acquired by Navigant Consulting, Inc.). Michael holds a BSE in Bioengineering from the University of Pennsylvania.

Michael Allen

Chief Financial Officer

Education

York University, MBA
Queens University, BA in Finance and Accounting

Mike Allen brings over 20 years of financial management experience and oversees Vatera Healthcare Partners’ financial operations. With his extensive experience in financial management and operations, Mike acts as a resource to our portfolio companies’ finance teams, in addition to handling all accounting and finance matters relating to the firm’s investment portfolio.

Prior to joining the firm in 2007, Mike was a Director and Member of the Operating Committee at GlobeOp LLC, where he managed a large team of Fund Accountants and Operations Specialists providing outsourced back-office operations and accounting services for multiple hedge funds in the U.S. and Europe across different strategies. Prior to GlobeOp, Mike had various controller and risk management roles with UBS in London and New York, including regional Head of Business Unit Control for UBS’ Equity Division in the Americas. Prior to that, Mike was with Price Waterhouse, where he started his career in the Assurance practice in Toronto and then transferred to the Financial Services Consultancy practice in London. Mike holds a BA in Finance and Accounting from Queens University in Canada and an MBA from York University in Canada.

Christopher Burden

Chief Operating Officer

Education

American University Law School, JD
Cornell University, BA in Government

Chris Burden draws on his more than 20 years of private equity legal and business experience to assist Vatera Healthcare Partners with a wide range of transactional and business management matters. His broad skill set, understanding of investment issues and previous legal experience enable him to add value to the team.

Chris joined the firm at its inception in 2007. Before that, he was with Ferro Capital LLC at its inception in 2001. Prior to that, he was the Head of Product Development for Commerzbank’s Alternative Investment Strategies Group. Before Commerzbank, Chris worked as an attorney in the Corporate Finance Department of the law firm Shearman & Sterling, and as an attorney in the Litigation Department of the law firm Willkie Farr & Gallagher. Chris holds a BA in Government from Cornell University and a JD from American University Law School.

Anna Kim

General Counsel

Education

Harvard Law School, JD
Harvard College, AB in History and Science

Anna Kim is responsible for Vatera Healthcare Partners’ legal, structuring and compliance-related activities. After over 15 years of practicing law, she has developed a wealth of experience both in complex transactions and in business management issues, Anna is an asset to the Vatera Healthcare Partners team in executing portfolio company transactions and in assisting and supplementing portfolio companies in the legal aspects of their business operations.

Before joining the firm in 2009, Anna was the Chief Legal Officer and Chief Compliance Officer of Tykhe Capital LLC. Prior to Tykhe Capital, Anna was Vice President and Assistant General Counsel at JPMorgan Chase & Co., and was the primary attorney for the Private Investments team at JP Morgan Private Bank. Anna was previously an attorney in the Investment Management Group at the law firm Davis Polk & Wardwell. Anna holds an AB in History and Science from Harvard College and a JD from Harvard Law School.